CA2355829A1 - Formes posologiques orale multiparticulaires - Google Patents

Formes posologiques orale multiparticulaires Download PDF

Info

Publication number
CA2355829A1
CA2355829A1 CA002355829A CA2355829A CA2355829A1 CA 2355829 A1 CA2355829 A1 CA 2355829A1 CA 002355829 A CA002355829 A CA 002355829A CA 2355829 A CA2355829 A CA 2355829A CA 2355829 A1 CA2355829 A1 CA 2355829A1
Authority
CA
Canada
Prior art keywords
oral dosage
dosage form
form according
active ingredient
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002355829A
Other languages
English (en)
Inventor
Louise Templeton
Janet Elizabeth Codd
Orla Mary Conaghey
Maurice Joseph Anthony Clancy
Kenneth Iain Cumming
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE990009A external-priority patent/IE990009A1/en
Application filed by Individual filed Critical Individual
Publication of CA2355829A1 publication Critical patent/CA2355829A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Abstract

La présente invention concerne une forme posologique orale commode contenant un médicament absorbé de façon réversible sur une résine d'échanges d'ions puis enrobée d'une matière polymère. Les compositions de l'invention conviennent particulièrement à la formulation de composés médicamenteux instables en milieu acide et/ou de composés médicamenteux au goût prononcé voire désagréable. L'invention concerne également, d'une part des procédés de fabrication de telles formes posologiques orales commodes, et d'autre part des formes posologiques finales incluant ces formes posologiques orales commodes.
CA002355829A 1999-01-07 2000-01-07 Formes posologiques orale multiparticulaires Abandoned CA2355829A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11507099P 1999-01-07 1999-01-07
IE990009 1999-01-07
US60/115,070 1999-01-07
IE990009A IE990009A1 (en) 1999-01-07 1999-01-07 Taste-masked composition
PCT/IE2000/000003 WO2000040224A1 (fr) 1999-01-07 2000-01-07 Formes posologiques orale multiparticulaires

Publications (1)

Publication Number Publication Date
CA2355829A1 true CA2355829A1 (fr) 2000-07-13

Family

ID=26320234

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002355829A Abandoned CA2355829A1 (fr) 1999-01-07 2000-01-07 Formes posologiques orale multiparticulaires

Country Status (5)

Country Link
EP (1) EP1140037A1 (fr)
JP (1) JP2002534374A (fr)
AU (1) AU1998200A (fr)
CA (1) CA2355829A1 (fr)
WO (1) WO2000040224A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020031490A1 (en) * 2000-07-27 2002-03-14 Bellamy Simon Andrew Method for preparing resinates
US20020032245A1 (en) * 2000-07-27 2002-03-14 Lyn Hughes Resinate composition
US20030059397A1 (en) * 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
JP4268052B2 (ja) * 2002-01-18 2009-05-27 ローム アンド ハース カンパニー レジネートの調製方法
JP2006506461A (ja) 2002-10-25 2006-02-23 コルジウム ファーマシューティカル， インコーポレイテッド ミルナシプランのパルス型放出組成物
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
JP2006513239A (ja) * 2002-12-23 2006-04-20 セルテック アメリカズ， インコーポレイテッド 酸不安定性薬剤含有組成物
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
CA2531564C (fr) * 2003-07-18 2016-01-19 Santarus, Inc. Formulations pharmaceutiques utilisees pour inhiber une secretion acide et procede de fabrication associe
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
KR101228233B1 (ko) 2004-03-30 2013-01-31 리립사, 인크. 이온 결합 중합체 및 이의 용도
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
KR101399238B1 (ko) * 2004-03-30 2014-05-27 리립사, 인크. 이온 결합 중합체 및 이의 용도
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
EP1747776A1 (fr) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique comprenant du pantoprazole granulaire
FR2891147B1 (fr) 2005-09-28 2007-12-07 Ethypharm Sa Comprimes orodispersibles de principes actifs amers
BRPI0616604A2 (pt) 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica
AU2006294455B2 (en) 2005-09-30 2013-06-20 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
EP1834634A3 (fr) * 2006-03-08 2007-10-03 Rentschler Pharma GmbH Composition pharmaceutique en multiple-unité
EP1837016A3 (fr) * 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique en multiple-unité
EP2428205B1 (fr) 2006-03-16 2012-10-03 Tris Pharma, Inc. Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions
ES2385498T3 (es) * 2006-08-18 2012-07-25 Evonik Röhm Gmbh Composición farmacéutica con liberación controlada de la sustancia activa, para sustancias activas con una buena solubilidad en agua
EP2044929A1 (fr) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Comprimés oraux à désintégration rapide
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
BR112013020537B1 (pt) * 2011-02-15 2021-09-08 Tris Pharma, Inc Suspensão oral e mescla de pó de liberação prolongada aquosa de metilfenidato, método para fornecer um produto em suspensão líquida de metilfenidato, e formulação
BR112015003120B1 (pt) 2012-08-15 2022-08-09 Tris Pharma , Inc Tablete mastigável de liberação estendida de metilfenidato e seu uso
JP6475624B2 (ja) 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
US10245284B2 (en) 2015-08-19 2019-04-02 Alpex Pharma S.A. Granular composition for oral administration
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
BR112019004910B1 (pt) 2016-09-28 2022-08-09 Dow Global Technologies Llc Artigo para tratamento de ar.
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN113710280A (zh) * 2019-10-10 2021-11-26 美国倍利年制药有限公司 基于微粉化药物树脂酸盐的药物组合物及其制备方法
CN114933344B (zh) * 2022-05-16 2023-11-24 西北大学 一种双官能团酸性离子交换吸附剂去除废水中氟喹诺酮类抗生素的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU63060A1 (fr) * 1971-04-26 1971-08-26
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
EP0943341A1 (fr) * 1998-02-18 1999-09-22 Oscar Gold Procédé pour préparer de compositions granulées qui contiennent macrolides d'érythromycine et procédé pour préparer des compositions pharmaceutiques qui contiennent ces macrolides

Also Published As

Publication number Publication date
JP2002534374A (ja) 2002-10-15
AU1998200A (en) 2000-07-24
EP1140037A1 (fr) 2001-10-10
WO2000040224A1 (fr) 2000-07-13

Similar Documents

Publication Publication Date Title
CA2355829A1 (fr) Formes posologiques orale multiparticulaires
US7029701B2 (en) Composition for the treatment and prevention of ischemic events
AU748445B2 (en) Omeprazole formulation
JP5845173B2 (ja) 非オピオイドおよびオピオイド鎮痛薬の組み合わせを含む口腔内崩壊錠組成物
EP1023051B1 (fr) Formulation multiparticulaire de morphine orale
US7294347B2 (en) Coating compositions for bitterness inhibition
JP4885347B2 (ja) 酸に不安定ベンズイミダゾールを含有する修飾された放出特性の経口用固形製剤
US20060115529A1 (en) Fast-melting tablets having taste-masking and sustained release properties
KR100675809B1 (ko) 맛을 차폐시킨 약제학적 액체 제제
HUT75164A (en) Opioid formulations having extended controlled release
SK31498A3 (en) Novel composition containing an acid-labile omeprazole and process for its preparation
CA2637444C (fr) Composition pharmaceutique de tolterodine enrobee ou sel de celle-ci presentant une dissolution rapide dans des conditions acides et une dissolution lente a des valeurs de ph pluselevees
US20070065513A1 (en) Stable lansoprazole formulation
SK18832000A3 (sk) Entericky potiahnutá farmaceutická tableta a spôsob jej prípravy
JP2001526213A (ja) 経口医薬パルス放出剤形
WO2001052816A2 (fr) Formulations pharmaceutiques de derives benzimidazole administrees par voie orale et procede de preparation de ces dernieres
US20100280035A1 (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier
MXPA01013046A (es) Formas de administracion oral para administrar una combinacion fija de tramadol y diclofenac.
JP4771956B2 (ja) バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物
US7060293B1 (en) Powder-layered oral dosage forms
US5258186A (en) Drug release controlling coating material for long acting formulations
AU6224699A (en) Taste masking coating compositions
WO2007054565A2 (fr) Nouvelle formulation galenique stabilisee comprenant du lansoprazole et sa preparation
CA2558783C (fr) Formulation orale multiparticulaire de morphine
IL293648A (en) Dosage form for use in the treatment or prevention of disease

Legal Events

Date Code Title Description
FZDE Dead